[Comment] MS-STAT2: lessons from negative trials in multiple sclerosis

00:00 - 01 Oct 2025

Treatment of multiple sclerosis has had extraordinary success in the past decade, with the availability of several disease-modifying treatments targeting different mechanisms involved in disease pathophysiology. Despite these advancements, approval of these drugs is largely limited to patients with relapsing-remitting disease given their proven efficacy on measures of inflammation (ie, annualised relapse rate or formation of inflammatory lesions at MRI) in phase 2 and phase 3 clinical trials. Use of these treatments in patients with progressive multiple sclerosis has yielded largely negative results, contributing to the gap of treatment accessibility for these forms of the disease.